A Bayesian mixed-treatment comparison meta-analysis of treatments for alcohol dependence and implications for

Stacia M DeSantis1, Huirong Zhu1

  • 1Division of Biostatistics, School of Public Health, University of Texas Health Science Center, Houston, TX, USA (SMD, HZ).

Abstract

Insights

Mixed treatment comparison meta-analysis improves alcohol dependence treatment estimates by incorporating indirect evidence. Combination therapy (naltrexone + acamprosate) shows the highest probability of being the best treatment.

Area of Science:

  • Addiction medicine
  • Biostatistics
  • Clinical trial design

Background:

  • Alcohol dependence treatments have been evaluated in randomized controlled trials, leading to systematic reviews and mixed treatment comparisons (MTCs).
  • The existing evidence network has limited direct comparisons between active treatments and has not fully incorporated indirect comparisons.
  • Inadequate analysis of treatment networks impacts the planning and efficiency of future clinical trials.

Purpose of the Study:

  • To apply advanced Bayesian MTC meta-analysis techniques to analyze the evidence network for alcohol dependence treatments.
  • To develop a methodology for informing, designing, and powering future clinical trials based on updated meta-analysis results.
  • To address the challenge of estimating treatment effects for infrequently compared interventions.

Main Methods:

  • Bayesian mixed treatment comparison (MTC) meta-analysis was employed to analyze the network of evidence for alcohol dependence treatments.
  • The methodology was developed using results from an updated meta-analysis to inform hypothetical trial design.
  • Analysis focused on incorporating both direct and indirect treatment comparisons within the evidence network.

Main Results:

  • MTC meta-analysis yielded more precise treatment effect estimates compared to traditional pairwise meta-analyses.
  • Decisive differences between active treatments, even those infrequently directly compared, were identified.
  • A combination treatment of naltrexone and acamprosate demonstrated the highest probability of being the most effective treatment based on weighted outcomes.
  • For a hypothetical trial comparing combination therapy to acamprosate alone, no feasible sample size could yield a decisive result.

Conclusions:

  • Mixed treatment comparison meta-analysis is recommended for estimating treatment effects in networks with consistent direct and indirect evidence.
  • This approach enhances the accuracy of treatment effect estimation and uncovers significant differences between interventions.
  • The methodology informs the design and power calculations for future clinical trials, optimizing resource allocation and study outcomes.

Related Concept Videos

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
710
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
11.5K
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
415
CNS Depressants: Alcohol and Nicotine01:27

CNS Depressants: Alcohol and Nicotine

Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
1.7K
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs01:20

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
407
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
752